Ixekizumab for refractory psoriatic arthritis

An Australian-led trial has shown that a biological DMARD targeting interleukin 17A has benefit in difficult-to-treat patients with psoriatic arthritis who have failed to improve on TNFalpha inhibitors.

In a phase 3 trial of ixekizumab in 363 patients refractory to, intolerant of, or showing loss of efficacy with TNF alpha treatment, the primary endpoint of 20% improvement in the American College of Rheumatology(ACR20) response criteria at 24 weeks was achieved by about half the patients compared with just a fifth of patients on placebo.

In the trial led by Professor Peter Nash